Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
QuintilesIMS
US Army
Deloitte
Boehringer Ingelheim
Queensland Health
McKesson
Accenture
Colorcon

Generated: December 15, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR METHYLPREDNISOLONE SODIUM SUCCINATE

« Back to Dashboard

Clinical Trials for Methylprednisolone Sodium Succinate

Trial ID Title Status Sponsor Phase Summary
NCT00000579 Acute Respiratory Distress Syndrome Clinical Network (ARDSNet) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 The purposes of this study are to assess rapidly innovative treatment methods in patients with adult respiratory distress syndrome (ARDS) as well as those at risk of developing ARDS and to create a network of interactive Critical Care Treatment Groups (CCTGs) to establish and maintain the required infrastructure to perform multiple therapeutic trials that may involve investigational drugs, approved agents not currently used for treatment of ARDS, or treatments currently used but whose efficacy has not been well documented.
NCT00290602 Early Low Dose Steroid Therapy of Acute Respiratory Distress Syndrome Completed National Cancer Center, Korea Phase 2 The purpose of this study is to determine whether the 2mg/kg administration of corticosteroids, in the form of methylprednisolone sodium succinate, in early phase acute respiratory distress syndrome after thoracic surgery, will reduce the postoperative mortality.
NCT00295269 Corticosteroids as Rescue Therapy for the Late Phase of Acute Respiratory Distress Syndrome Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 The purpose of this study is to assess innovative treatment methods in patients with adult respiratory distress syndrome (ARDS) as well as those at risk of developing ARDS.
NCT01046786 Safety and Feasibility of Umbilical Cord Blood Cell Transplant Into Injured Spinal Cord Completed Chinese University of Hong Kong Phase 1/Phase 2 To investigate the feasibility, safety, efficacy and optimal dose of umbilical cord blood mononuclear cell transplant in the treatment of chronic spinal cord injuries.
NCT01046786 Safety and Feasibility of Umbilical Cord Blood Cell Transplant Into Injured Spinal Cord Completed The University of Hong Kong Phase 1/Phase 2 To investigate the feasibility, safety, efficacy and optimal dose of umbilical cord blood mononuclear cell transplant in the treatment of chronic spinal cord injuries.
NCT01046786 Safety and Feasibility of Umbilical Cord Blood Cell Transplant Into Injured Spinal Cord Completed China Spinal Cord Injury Network Phase 1/Phase 2 To investigate the feasibility, safety, efficacy and optimal dose of umbilical cord blood mononuclear cell transplant in the treatment of chronic spinal cord injuries.
NCT01354483 Umbilical Cord Blood Mononuclear Cell Transplant to Treat Chronic Spinal Cord Injury Completed Chengdu PLA General Hospital Phase 1/Phase 2 The purpose of this study is to investigate the feasibility, safety, efficacy and optimal dose of umbilical cord blood mononuclear cell transplant in the treatment of chronic spinal cord injuries.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Methylprednisolone Sodium Succinate

Condition Name

Condition Name for Methylprednisolone Sodium Succinate
Intervention Trials
Lung Diseases 2
Acute Respiratory Distress Syndrome 2
Spinal Cord Injuries 2
Neurotoxicity Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Methylprednisolone Sodium Succinate
Intervention Trials
Acute Lung Injury 3
Syndrome 3
Respiratory Distress Syndrome, Newborn 3
Respiratory Distress Syndrome, Adult 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Methylprednisolone Sodium Succinate

Trials by Country

Trials by Country for Methylprednisolone Sodium Succinate
Location Trials
United States 67
Canada 9
Australia 5
Hong Kong 2
New Zealand 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Methylprednisolone Sodium Succinate
Location Trials
North Carolina 3
Maryland 3
Massachusetts 3
Texas 2
Minnesota 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Methylprednisolone Sodium Succinate

Clinical Trial Phase

Clinical Trial Phase for Methylprednisolone Sodium Succinate
Clinical Trial Phase Trials
Phase 4 3
Phase 3 4
Phase 2 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Methylprednisolone Sodium Succinate
Clinical Trial Phase Trials
Completed 7
Not yet recruiting 2
Recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Methylprednisolone Sodium Succinate

Sponsor Name

Sponsor Name for Methylprednisolone Sodium Succinate
Sponsor Trials
National Cancer Institute (NCI) 2
National Heart, Lung, and Blood Institute (NHLBI) 2
China Spinal Cord Injury Network 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Methylprednisolone Sodium Succinate
Sponsor Trials
Other 13
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Cantor Fitzgerald
Argus Health
Julphar
Mallinckrodt
Citi
Chinese Patent Office
Healthtrust
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.